Carcinoma, Hepatocellular
Conditions
Keywords
Transarterial chemoembolization, Lenvatinib, Carcinoma, Hepatocellular
Brief summary
This is a multicenter, prospective, observational study in which subjects will be treated with lenvatinib combined with TACE in un-resectable HCC patients who had not received systematic treatment or TACE treatment in the past.
Detailed description
Only 30% of HCC patients received radical resection. Most of the patients are in the advanced stage and can only receive palliative treatment such as TACE or systemic treatment. Lenvatinib is a multi-target receptor tyrosine kinase inhibitor (TKI), which mainly inhibits vascular endothelial growth factor(VEGF) receptor-1, 2, 3; fibroblast growth factors(FGF) receptor-1, 2, 3, 4; platelet derived growth factor receptor(PDGFR)α; RET and KIT and showed significant anti-tumor effect in REFLECT study. The purpose of this study is to explore the efficacy and safety of Lenvatinib and TACE in unresectable HCC patients.
Interventions
DRUGLenvatinib
Lenvatinib capsules will be administered orally, once daily (for patients \<60kg, lenvatinib 8mg po; for patients ≥60kg, lenvatinib 12mg po)
PROCEDURETACE
TACE will be performed as needed.
Sponsors
Zhejiang Cancer Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Ages of ≥ 18 and ≤ 75 years old. 2. Clinically or histopathologically diagnosed as hepatocellular carcinoma (HCC). 3. China stage IIb-IIIb patients, not suitable for surgical resection. 4. The imaging examination within 2 weeks before interventional therapy showed that there was at least one target lesion that could be measured by CT or MRI, and the lesion was suitable for repeated and accurate measurement. 5. Child-Pugh scores ≤7. 6. ECOG：0-1. 7. Intended to be treated with TACE combined with lenvatinib. 8. Good organ and bone marrow function: Blood routine: WBC\>4.0×109/L、Hb\>80g/L, PLT\>75×109/L, NEUT\>1.5×10⁹/L. Blood coagulation function: International normalized ratio (INR)\<1.2. Hepatic function: serum albumin (ALB)\>3.5 g/dl, total bilirubin (TBIL) \<1.5 × normal upper limit (ULN) (Eliminate biliary obstruction), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 3 × ULN. Renal dysfunction：serum creatinine (SCR) \<1.5× ULN. 9. Agreed to join the clinical trial and sign the informed consent form.
Exclusion criteria
1. Hepatobiliary cell carcinoma, mixed cell carcinoma and fibrolamellar hepatocellular carcinoma. 2. With invasion of the main portal vein or vena cava. 3. Received interventional therapy such as TACE within 2 years. 4. Received systematic treatment in the past. 5. Uncontrollable ascites, hepatic encephalopathy or esophagogastric variceal bleeding. 6. Patients with hypertension who cannot be reduced to normal range after antihypertensive treatment (systolic blood pressure \> 140mmHg, or diastolic blood pressure \> 90 mmHg). 7. Suffering from grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmia or myocardial ischemia or myocardial infarction (The QTc interval ≥ 450ms, QTc interval is calculated by Fridericia formula). 8. There is a history of gastrointestinal bleeding or a clear tendency of gastrointestinal bleeding in the past 3 months, such as esophageal varices at risk of bleeding, local active ulcer lesions, fecal occult blood ≥ (+). 9. Pregnant or lactating women. A fertile patient who is unwilling or unable to use effective contraception. 10. Patients with HIV infection. 11. Suspected allergy to research drugs. 12. Other situations which the researchers considered ineligible for participating in the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate（ORR） | up to 12 months | The percentage of patients who have best overall response of complete response (CR) or partial response (PR) according to mRECIST. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intrahepatic ORR and Extrahepatic ORR | up to 12 months | The percentage of patients who have best overall response of complete response (CR) or partial response (PR) according to mRECIST intrahepatic or extrahepatic, respectively. |
| Progression-free survival (PFS) | up to 12 months | The time from the beginning of treatment of TACE to the time of tumor progression or death from any cause (according to mRECIST standard) |
| Alpha-fetoprotein (AFP) response rate | up to 12 months | A decrease in AFP of more than 20% in AFP+ patients treated with lenvatinib is defined as an AFP response.AFP response rate defined as the percentage of AFP response patients in all AFP positive patients. |
| Time to progression（TTP） | up to 12 months | The time from the beginning of treatment of TACE to the time of tumor progression. (according to mRECIST standard) |
| Adverse events(AEs) | up to 18 months | AEs(adverse events) evaluated by the CTC-AE 5.0 |
Contacts
Primary ContactGuoliang Shao, Professor
Outcome results
None listed